# Insitro signs AstraZeneca discovery agreement with $40 million upfront payment

_Published Thursday, October 15, 2026 at 7:18 AM EDT · AI, Products · Latest · Tier 2 — Notable_

![Insitro signs AstraZeneca discovery agreement with $40 million upfront payment — Primary](https://s.yimg.com/lo/mysterio/api/6e19d81187d2166bf3fd6b64498793c6c2b962a7c8e954e8d7fd1c8fa3ee18d9/lightyear_networkapi/resizefill_w1200%3Bquality_80%3Bformat_webp/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fbusiness-wire.com%2F71623f087398f900b8f247e951e45aef.jpg)

Insitro announced a worldwide exclusive research agreement with AstraZeneca to discover drug targets and therapeutics for metabolic dysfunction-associated steatohepatitis, or MASH, and cardiomyopathies. Insitro will receive $40 million upfront and is eligible for up to approximately $1.46 billion in potential discovery, development and commercial milestone payments, plus single-digit royalties on potential global sales.

Insitro will use its Virtual Human AI platform to identify biological drivers of disease and advance AstraZeneca-nominated targets through selection of development candidates. AstraZeneca will lead clinical development, regulatory work and commercialization. The milestone payments depend on future progress; the agreement begins with discovery research.

## Sources

- [Yahoo Finance](https://finance.yahoo.com/healthcare/articles/insitro-announces-strategic-collaboration-astrazeneca-100000993.html)

---
Canonical: https://techandbusiness.org/newswire/DGBzUv15adrylE0hncI6fO
Published: 2026-10-15T11:18:44.265Z
Story chronology: 2026-10-15T10:00:00.000Z
Retrieved: 2026-10-15T14:47:22.781Z
Publisher: Tech & Business (techandbusiness.org)